GALT Galectin Therapeutics Inc.

1.91
+0.03  (2%)
Previous Close 1.88
Open 1.91
Price To book -21.22
Market Cap 66948757
Shares 35,051,705
Volume 99,410
Short Ratio 6.11
Av. Daily Volume 154,215

SEC filingsSee all SEC filings

  1. 8-K - Current report 171098128
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171077410
  3. 8-K/A [Amend] - Current report 171040128
  4. 8-K - Current report 171027269
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171027218

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 6, 2017.
GR-MD-02
Plaque psoriasis
Phase 2a primary endpoint not met - September, 27 2016.
GR-MD-02
Nonalcoholic steatohepatitis (NASH)
Phase 2a interim data released May 2016
GR-MD-02
moderate-to-severe plaque psoriasis.
Phase 2b top-line data due December 2017.
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis